CAMP4 Therapeutics (CAMP) vs Vicore Pharma AB (VCRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Vicore Pharma AB is the larger company by market cap ($242.8 million vs $230.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAMP | VCRE |
|---|---|---|
| Share price | $3.68 | $8.62 |
| Market cap | $230.62M | $242.78M |
| 1-day change | -4.28% | -0.46% |
| YTD return | -37.36% | — |
| 1-year return | +16.72% | — |
| EPS (TTM) | $-2.32 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.75 | $17.80 |
| 52-week low | $2.86 | $7.88 |
| Distance from 52-week high | -52.58% | -51.57% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +187.62% | +284.69% |
| Average volume | 277.90K | 16.24K |
| Shares outstanding | 62.75M | 28.16M |
| Employees | 48 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About CAMP4 Therapeutics
CAMP stock →Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Vicore Pharma AB
VCRE stock →Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 46 employees
CAMP vs VCRE FAQ
Which is bigger, CAMP4 Therapeutics or Vicore Pharma AB?
Vicore Pharma AB (VCRE) is larger, with a market capitalization of $242.78M compared with $230.62M for CAMP4 Therapeutics (CAMP).
Are CAMP4 Therapeutics and Vicore Pharma AB in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.